CIK 0001789972 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2023 | FY2022 | FY2021 | |
|---|---|---|---|
| Revenue (USD) | 0 | 0 | |
| Net income (USD) | 111.2 M | -65.6 M | -51.8 M |
| Diluted EPS (USD/shares) | -3.69 | -1.52 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-02 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-10-01 |
| 2026-09-24 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-09-24 |
| 2026-09-14 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-09-13 |
| 2026-09-10 | 4 | 4 | 2026-09-08 |
| 2026-09-08 | 144 | 144 | |
| 2026-08-14 | 4 | 4 | 2026-08-13 |
| 2026-08-14 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-13 | 144 | 144 | |
| 2026-08-13 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-08-12 |
| 2026-08-07 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-06 |
| 2026-07-07 | 4 | 4 | 2026-07-06 |
| 2026-07-06 | 144 | 144 | |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-07-02 | 4 | 4 | 2026-06-30 |
| 2026-06-18 | 4 | 4 | 2026-06-16 |
| 2026-06-18 | 4 | 4 | 2026-06-16 |
| 2026-06-18 | 4 | 4 | 2026-06-16 |
| 2026-06-18 | 4 | 4 | 2026-06-16 |
| 2026-06-18 | 4 | 4 | 2026-06-16 |
| 2026-06-18 | 4 | 4 | 2026-06-16 |
| 2026-06-16 | 8-K | 8-K items 5.07 | 2026-06-16 |
| 2026-06-10 | 8-K | 8-K items 7.01,8.01,9.01 | 2026-06-10 |
Forms on file (last 1,000): 4 220, 8-K 66, 3 27, 144 20, 10-Q 17, SC 13G/A 16, SC 13G 12, SCHEDULE 13G/A 10. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=CGEM (0.002 USD), /gw/filings/filings?ticker=CGEM&form=8-K, /gw/filings/facts?ticker=CGEM&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange